Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) over five years because of the United States' request for confidential information.
The decision was revealed after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government representative later clarified that the US was demanding access to health data for research and profit but was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate task of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more talks to find a deal agreeable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Implications
This development follows a comparable case in neighbouring Kenya, where a court blocked a similar deal with the US after concerns were raised about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and responsibility.
As per statements, Sixteen nations in Africa have to date signed similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be accessible to our citizens if a future pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining structures previously set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This framework is designed to guarantee that when a nation contributes its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing dialogue with our US partners on how future collaboration could be designed in a way that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the official position, but recommended that negotiations need to persist since a large portion of the nation's Aids initiatives relied on external financing.
"If specific concerns exist, including those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," the group said.
The situation emphasises the ongoing challenges between receiving much-needed foreign assistance and safeguarding a country's data in an increasingly interconnected world.